
© 2025 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
134,76 | 135,84 | 13:04 | |
0,000 | 0,000 | 16.05. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mi | Genmab A/S: Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress | Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings Genmab... ► Artikel lesen | |
Mi | Genmab stock price target cut to $35 at H.C. Wainwright | ||
Mo | GENMAB A/S - 6-K, Report of foreign issuer | ||
Mo | Genmab A/S: Transactions in Connection with Share Buy-back Program | ||
09.05. | Genmab reports Q1 results |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | Weighing approval bids from J&J, Pfizer and Roche, FDA scrutinizes data ahead of adcomm | ||
Mi | Johnson & Johnson's bladder cancer therapy Balversa accepted by SMC | ||
Di | 13 Analysts Have This To Say About Johnson & Johnson | ||
Di | J&J, Halozyme cut at Leerink on price control risk for combo products | ||
Di | Leerink cuts Johnson & Johnson stock rating on Darzalex concerns |